Pamisel, Foreign Investors Net Buy 42,000 Shares... Stock Price Up 0.23%

Pamisell has ranked among the top searched stocks for 8 days in the past month.

As of 11:30 AM on the 4th, Pamisell is trading at 21,900 KRW, up 0.23% from the previous day. This marks a 16.49% increase compared to November 6. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.

Today, foreigners have net purchased 42,000 shares of Pamisell, while institutions have net sold 3,000 shares, according to provisional data. Over the past 5 days, individual investors have net purchased 328,260 shares, while foreigners and institutions have net sold 340,587 shares and net purchased 12,932 shares, respectively.

On December 3, Pamisell was a market topic with the headline "Strong performance following approval of phase 3 clinical trial for liver cirrhosis stem cell therapy."

[Table] Foreigners and Institutions Net Trading Volume (Unit: shares)

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.